AbbVie, EvolveImmune Therapeutics Strike Deal to Develop Biotherapeutics for Resistant Cancer Cells

The deal is expected to leverage EvolveImmune’s T-cell engager EVOLVE platform to develop novel antibody-based therapies for solid and hematologic malignancies.